Orient EuroPharma Co., Ltd.
Taipei ExchangeTotal Valuation
Orient EuroPharma Co., Ltd. carries a market capitalization of 4.00B, placing it among publicly traded companies globally. Its enterprise value stands at 6.09B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 4.00B |
| Enterprise Value | 6.09B |
Share Statistics
Orient EuroPharma Co., Ltd. currently has 86.75M shares outstanding.
| Shares Outstanding | 86.75M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 0.84, and the price-to-book ratio stands at 0.96.
| PE Ratio | N/A |
| PS Ratio | 0.84 |
| PB Ratio | 0.96 |
| P/TBV Ratio | 0.53 |
| P/FCF Ratio | -37.41 |
| P/OCF Ratio | -13.26 |
Enterprise Valuation
| EV / Sales | 1.32 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 228.12 |
Financial Position
Orient EuroPharma Co., Ltd. maintains a current ratio of 1.47, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 44.46, indicating elevated leverage, while an interest coverage ratio of -4.03 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.47 |
| Quick Ratio | 0.73 |
| Debt / Equity | 44.46 |
| Debt / EBITDA | -10.94 |
| Interest Coverage | -4.03 |
Financial Efficiency
| Return on Equity (ROE) | -17.42 |
| Return on Assets (ROA) | -4.77 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | -3.34 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.23 |
Taxes
Over the trailing twelve months, Orient EuroPharma Co., Ltd. has paid 207.16M in income taxes, reflecting an effective tax rate of 140.30.
| Income Tax | 207.16M |
| Effective Tax Rate | 140.30 |
Stock Price Statistics
Orient EuroPharma Co., Ltd.'s stock has declined approximately -17.67857% over the past 52 weeks. The 50-day moving average sits at 45.85, while the 200-day moving average is 46.01.
| Beta (5Y) | N/A |
| 52-Week Price Change | -17.67857% |
| 50-Day Moving Average | 45.85 |
| 200-Day Moving Average | 46.01 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Orient EuroPharma Co., Ltd. generated 4.60B in revenue and converted that into -567.39M in net income, yielding earnings per share of -5.55. EBITDA reached -298.82M, while operating income came in at -298.82M.
| Revenue | 4.60B |
| Gross Profit | 2.24B |
| Operating Income | -298.82M |
| Pretax Income | -273.03M |
| Net Income | -567.39M |
| EBITDA | -298.82M |
| EBIT | -298.82M |
| Earnings Per Share (EPS) | -5.55 |
Balance Sheet
Orient EuroPharma Co., Ltd. holds 2.12B in cash and equivalents against 3.27B in total debt, resulting in a net debt position of 986.00M. Total book value stands at 4.05B, with working capital of 1.38B providing operational flexibility.
| Cash & Cash Equivalents | 2.12B |
| Total Debt | 3.27B |
| Net Debt | 986.00M |
| Equity (Book Value) | 4.05B |
| Book Value Per Share | 46.79 |
| Working Capital | 1.38B |
Cash Flow
Orient EuroPharma Co., Ltd. produced -292.21M in operating cash flow over the past twelve months. After subtracting -188.64M in capital expenditures, free cash flow totaled -480.85M - equivalent to -5.56 per share.
| Operating Cash Flow | -292.21M |
| Capital Expenditures | -188.64M |
| Free Cash Flow | -480.85M |
| FCF Per Share | -5.56 |
Margins
Orient EuroPharma Co., Ltd. operates with a gross margin of 48.69, reflecting its pricing power and cost economics. The operating margin of -6.50 and net profit margin of -12.35 provide insight into operational efficiency.
| Gross Margin | 48.69 |
| Operating Margin | -6.50 |
| Pretax Margin | -5.94 |
| Profit Margin | -12.35 |
| EBITDA Margin | -6.50 |
Dividends & Yields
The company's payout ratio of -23.42 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 1.06 |
| Dividend Yield | N/A |
| Payout Ratio | -23.42 |
| Shareholder Yield | 12.47 |
| FCF Yield | -2.67 |
Stock Splits
Orient EuroPharma Co., Ltd.'s most recent stock split took place on July 28, 2010 with a 25:29 split ratio.
| Last Split Date | 7/28/2010 |
| Split Ratio | 25:29 |
Scores
Orient EuroPharma Co., Ltd. posts an Altman Z-Score of 1.28, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.28 |